Rock Springs Capital Management LP Clovis Oncology, Inc. Transaction History

Rock Springs Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$3.0 - $16.43 $768,000 - $4.21 Million	-256,000 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$11.63 - $32.67 $175,613 - $493,317	-15,100 Reduced 5.57%	256,000 $4.6 Million
Q3 2018 Nov 14, 2018	BUY	$29.37 - $49.48 $472,857 - $796,628	16,100 Added 6.31%	271,100 $7.96 Million
Q2 2018 Aug 14, 2018	BUY	$42.06 - $62.4 $988,410 - $1.47 Million	23,500 Added 10.15%	255,000 $11.6 Million
Q3 2017 Nov 14, 2017	BUY	$67.17 - $84.81 $15.5 Million - $19.6 Million	231,500	231,500 $19.1 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Rock Springs Capital Management LP with notifications on news.